Hematology News

The emerging use of artificial intelligence in health care presents a new set of ethical issues for clinicians to consider.

In a special scientific session on race and science at ASH Annual Meeting an Exposition, Saad Z. Usmani, MD, MBA, FACP, FRCP, examined clinical trial inclusion from an investigator’s perspective.

Alexis Thompson, MD, MPH, is an optimist.

SAN DIEGO — Individuals with sickle cell trait are at increased risk for leukemia, specifically myeloid and monocytic leukemias, according to data presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Efanesoctocog alfa prophylaxis is conventionally cost-ineffective compared with standard factor VIII for patients with severe hemophilia A without inhibitors, according to results presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Guideline-directed use of hydroxyurea may reduce cerebrovascular disease among individuals with sickle cell disease, according to single-center study results.

SAN DIEGO — Social media listening can provide clinicians with a novel and valuable method of identifying challenges and unmet needs of patients with sickle cell disease that they otherwise might not share during medical visits.

SAN DIEGO — Emicizumab exhibited efficacy for infants with severe hemophilia A without factor VIII inhibitors, according to study results presented at ASH Annual Meeting and Exposition.

SAN DIEGO — One-time treatment with lovotibeglogene autotemcel gene therapy conferred “transformative” benefit to patients with sickle cell disease, according to a presenter at ASH Annual Meeting and Exposition.

Women received significantly fewer academic research grants compared with men in hematology, although some agencies have shown progress in closing the gender disparity, according to results presented at ASH Annual Meeting and Exposition.